Octapharma AG - Home
EN: Navigation mit Access Keys
[Alt + 0] - Startseite
[Alt + 1] - Navigation
[Alt + 2] - Inhalt
[Alt + 3] - Kontakt
[Alt + 4] - Sitemap
[Alt + 5] - Suche
EN: Hauptnavigation
About Octapharma
Corporate Profile
Products & Therapies
Safety & Quality
Product Development
News & Events
Career
Healthcare Professionals
Products & Therapies
Product Development
Safety & Quality
8 Questions
Patients
Our Commitment
Disease & Therapies
Patient Stories
Plasma Donations
8 Questions
Contact
Type your search here...
Octapharma news & events
Octapharma USA appoints David E. Holliday as Vice President of Commercial Development
12.01.2012
more
Approval of Dedicated Step for Specific Prion Removal and Second Manufacturing Site for octaplas® Through a Mutual Recognition Procedure in Europe
23.11.2011
more
Octapharma Reports octagam® 5% and octagam® 10% Global Sales Totaled 1.7 Million Grams Through October With No Thromboembolic Events
14.11.2011
more
Meet Octapharma
Octapharma's Corporate Video
As a world-wide provider of human proteins as treatments in immunotherapy, haematology, and intensive care and emergency medicine, Octapharma is constantly investing in the renovation and modernisation of our plants.
Wolfgang Marguerre Chairman of the Board
As a world-wide provider of human proteins as treatments in immunotherapy, haematology, and intensive care and emergency medicine, Octapharma is constantly investing in the renovation and modernisation of our plants.